From: Sex-specific role of epigenetic modification of a leptin upstream enhancer in adipose tissue
Cohort | N | Median [IQR] | Female | Male | Female vs. male | |||
---|---|---|---|---|---|---|---|---|
N | Median [IQR] | N | Median [IQR] | P-value | ||||
BMI [kg/m2] | Total | 518 | 48.1 [41.9–53.7] | 339 | 47.1 [41.8–52.7] | 179 | 50.0 [42.6–54.7] | 0.065 |
Methylation subset | 52 | 49.0 [41.5–52.6] | 31 | 46.5 [39.6–51.0] | 21 | 52.0 [47.7–57.6] | 0.031 | |
Age [y] | Total | 518 | 50.4 [40.1–57.0] | 339 | 50.5 [40.8–57.0] | 179 | 50.1 [39.2–57.2] | 0.716 |
Methylation subset | 52 | 50.0 [39.3–56.8] | 31 | 54.0 [40.9–57.4] | 21 | 48.3 [35.2–53.5] | 0.376 | |
Body fat [%] | Total | 511 | 48.8 [41.9–54.3] | 337 | 52.0 [47.0–57.1] | 174 | 41.8 [37.0–46.8] | 6.19E−33 |
Methylation subset | 52 | 47.3 [40.6–55.8] | 31 | 54.5 [42.0–58.7] | 21 | 44.8 [39.8–48.0] | 0.017 | |
TSH [mU/l] | Total | 510 | 1.6 [1.0–2.2] | 335 | 1.5 [0.9–2.2] | 175 | 1.7 [1.1–2.2] | 0.072 |
Methylation subset | 52 | 1.9 [1.2–2.4] | 31 | 1.8 [1.2–2.4] | 21 | 1.9 [1.2–2.4] | 0.963 | |
fT3 [pmol/l] | Total | 327 | 4.9 [4.3–5.4] | 212 | 4.8 [4.2–5.3] | 115 | 5.2 [4.5–5.6] | 0.002 |
Methylation subset | 46 | 5.0 [4.7–5.4] | 27 | 5.0 [4.6–5.3] | 19 | 5.2 [4.7–5.6] | 0.289 | |
fT4 [pmol/l] | Total | 338 | 16.6 [14.6–18.9] | 222 | 17.0 [14.8–19.4] | 116 | 15.6 [14.5–18.1] | 0.011 |
Methylation subset | 48 | 17.0 [14.9–19.7] | 29 | 18.4 [15.8–21.6] | 19 | 15.8 [14.8–17.5] | 0.058 | |
LEP mRNA level [AU] | Total | 518 | 12.2 [11.5–13.0] | 339 | 12.1 [11.4–12.9] | 179 | 12.5 [11.6–13.2] | 0.045 |
Methylation subset | 52 | 12.3 [11.4–13.0] | 31 | 12.3 [11.3–12.9] | 21 | 12.7 [11.5–13.9] | 0.274 | |
LEP serum level [ng/µl] | Total | 485 | 40.2 [25.8–54.8] | 315 | 41.9 [30.4–57.8] | 170 | 31.2 [17.9–47.9] | 4.70E−07 |
Methylation subset | 50 | 41.6 [35.9–50.4] | 30 | 43.4 [36.4–51.3] | 20 | 41.1 [34.9–47.3] | 0.434 | |
LEP UE meth. [%]* | Methylation subset | 52 | 63.5 [56.3–67.7] | 31 | 65.3 [60.8–68.5] | 21 | 59.1 [53.2–65.5] | 0.031 |